Oncolytic Viral Therapy Development for Breast Cancer

Oncolytic viruses are a unique class of therapeutic agents that possess the remarkable ability to selectively infect and destroy cancer cells, while leaving healthy tissues unharmed. As a premier preclinical CRO, Alfa Cytology offers comprehensive services in the development and evaluation of oncolytic viral for breast cancer therapy.

Introduction to Oncolytic Viral Therapy

Oncolytic virus (OVs) refers to the general term for viruses that are naturally occurring or gene-edited and can selectively kill tumor cells. In principle, the physiological and metabolic environment in tumor cells is different from that of normal cells. Due to its characteristics, OVs can infect tumor cells and selectively replicate in tumor cells, leading to the dissolution and death of tumor cells. At the same time, it cannot or can only be replicated in a small amount in normal cells, so as to avoid affecting normal cells. OVs therapy has strong anti-tumor specificity, good effects, and few side effects, and has broad prospects for development in the direction of targeted therapy for breast cancer (BC).

Fig.1 Oncolytic virotherapy can be delivered in a variety of ways. (Soldozy S, et al., 2023)

Our Services

Alfa Cytology can provide you with oncolytic viral therapy development services for BC. Our services include:

• Production of native Ovs
  Oncolytic virus production steps mainly include cell culture, virus infection replication and large-scale culture, virus collection and purification, quality testing, etc. With the advanced technology platform and systematic workflow, we can better carry out virus culture amplification and downstream purification.
• Design and construction of artificially modified Ovs
  We can artificially modify OVs according to your needs to overcome some shortcomings of natural virus strains, such as deleting certain disease-causing genes, inserting exogenous therapeutic genes, and even adding new anti-cancer mechanisms.
• In vivo and in vitro detection of OVs
  For a comprehensive understanding of the therapeutic efficacy and further availability of designed oncolytic therapies, we provide in vivo and in vitro validation tests. In vivo tests include identity assays, transgene expression assays, transgene function assays, and cytopathic effect assays. In vitro tests include tumor lysis assays, immunogenicity, biodistribution/PK, and pharmacodynamic toxicity testing.

Advantages of Oncolytic Viral Therapy

• OVs have a natural synergy with various anticancer drugs and therapies (including chemotherapy drugs, targeted therapy, and cell therapy), which can create better anticancer therapies.
• OVs can be modified and regulated to control their influence on normal cells, so this therapy is expected to have few side effects and high safety.
• There are also many possibilities for the modification of OVs, which can further enhance the killing ability of tumor cells.
• Oncolytic virus therapy is suitable for most solid tumors.

Alfa Cytology' team is composed of highly educated and highly qualified professionals with good professional backgrounds and BC research experience. We have a complete set of BC therapy development technology. If you are interested in learning more about our BC therapy development services, please contact us. Our professional and patient staff will get in touch with you as soon as possible.